Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
22 Jun 2023
22 Jun 2023
Historique:
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
epublish
Résumé
Poly (ADP-ribose) polymerase inhibitors (PARPi) are used for patients with
Identifiants
pubmed: 38076873
doi: 10.1101/2023.06.22.544406
pmc: PMC10705575
pii:
doi:
Types de publication
Preprint
Langues
eng